|
EP2342340A1
(en)
|
2008-09-22 |
2011-07-13 |
Rxi Pharmaceuticals Corporation |
Rna interference in skin indications
|
|
EP3560503B1
(en)
|
2010-03-24 |
2021-11-17 |
Phio Pharmaceuticals Corp. |
Rna interference in dermal and fibrotic indications
|
|
CN103200945B
(zh)
|
2010-03-24 |
2016-07-06 |
雷克西制药公司 |
眼部症候中的rna干扰
|
|
UA117466C2
(uk)
|
2012-12-13 |
2018-08-10 |
Мерк Шарп Енд Доме Корп. |
СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
|
|
TWI715587B
(zh)
|
2015-05-28 |
2021-01-11 |
美商安可美德藥物股份有限公司 |
Ｔｉｇｉｔ結合劑和彼之用途
|
|
MX2019006072A
(es)
|
2016-11-30 |
2019-08-14 |
Oncomed Pharm Inc |
Metodos para tratamiento de cancer que comprenden agentes de enlace al inmunoreceptor de celulas t con dominios ige itim (tigit).
|
|
AU2018219887B2
(en)
|
2017-02-08 |
2024-08-15 |
Dragonfly Therapeutics, LLC |
Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
|
|
CN110944661A
(zh)
|
2017-02-20 |
2020-03-31 |
蜻蜓疗法股份有限公司 |
结合her2、nkg2d和cd16的蛋白质
|
|
EP3615070A1
(en)
|
2017-04-26 |
2020-03-04 |
Bristol-Myers Squibb Company |
Methods of antibody production that minimize disulfide bond reduction
|
|
LT3618863T
(lt)
|
2017-05-01 |
2023-10-10 |
Agenus Inc. |
Anti-tigit antikūnai ir jų panaudojimo būdai
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
JP7382232B2
(ja)
|
2017-05-02 |
2023-11-16 |
メルク・シャープ・アンド・ドーム・エルエルシー |
抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤
|
|
KR102770786B1
(ko)
*
|
2017-05-02 |
2025-02-20 |
머크 샤프 앤드 돔 엘엘씨 |
항-tigit 항체 단독의, 및 프로그램화된 사멸 수용체 1 (pd-1) 항체와 조합된 항-tigit 항체의 안정한 제제 및 그의 사용 방법
|
|
JP7348072B2
(ja)
|
2017-06-01 |
2023-09-20 |
コンピュジェン リミテッド |
三重併用抗体療法
|
|
WO2018229163A1
(en)
|
2017-06-14 |
2018-12-20 |
King's College London |
Methods of activating v delta 2 negative gamma delta t cells
|
|
AU2018301393B2
(en)
|
2017-07-11 |
2025-02-27 |
Compass Therapeutics Llc |
Agonist antibodies that bind human CD137 and uses thereof
|
|
EP3664817A4
(en)
*
|
2017-08-07 |
2021-09-22 |
Phio Pharmaceuticals Corp. |
CHEMICALLY MODIFIED OLIGONUCLEOTIDES
|
|
WO2019037052A1
(zh)
*
|
2017-08-24 |
2019-02-28 |
深圳市博奥康生物科技有限公司 |
靶向沉默wucam的shrna
|
|
CN108558997B
(zh)
*
|
2017-10-20 |
2021-10-08 |
中国人民解放军第四军医大学 |
一种重组融合蛋白TIGIT-Fc及其抗移植排斥反应的应用
|
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
|
EP3713961A2
(en)
|
2017-11-20 |
2020-09-30 |
Compass Therapeutics LLC |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
|
CA3237846A1
(en)
|
2018-02-08 |
2019-08-15 |
Dragonfly Therapeutics, Inc. |
Antibody variable domains targeting the nkg2d receptor
|
|
BR112020015994A2
(pt)
|
2018-02-08 |
2020-12-15 |
Dragonfly Therapeutics, Inc. |
Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer
|
|
WO2019164930A1
(en)
|
2018-02-20 |
2019-08-29 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
|
|
MX2020008795A
(es)
|
2018-02-28 |
2020-10-08 |
Yuhan Corp |
Anti cuerpos anti tigit y usos de los mismos.
|
|
AU2019235900B2
(en)
*
|
2018-03-14 |
2025-12-11 |
Dana-Farber Cancer Institute, Inc. |
Engineered cells, T cell immune modulating antibodies and methods for using the same
|
|
KR102835308B1
(ko)
|
2018-08-08 |
2025-07-21 |
드래곤플라이 쎄라퓨틱스, 인크. |
Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
|
|
EP3833392A4
(en)
|
2018-08-08 |
2022-05-18 |
Dragonfly Therapeutics, Inc. |
MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
JP2021534196A
(ja)
|
2018-08-23 |
2021-12-09 |
シージェン インコーポレイテッド |
抗ｔｉｇｉｔ抗体
|
|
KR102084196B1
(ko)
*
|
2018-08-29 |
2020-03-03 |
연세대학교 산학협력단 |
면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트
|
|
WO2020081408A1
(en)
|
2018-10-18 |
2020-04-23 |
Merck Sharp & Dohme Corp. |
Formulations of anti-rsv antibodies and methods of use thereof
|
|
MX2021004928A
(es)
|
2018-10-31 |
2021-06-08 |
Merck Sharp & Dohme Llc |
Cristales de anticuerpo anti-pd-1 humano y metodos de uso de los mismos.
|
|
EP3876990A4
(en)
|
2018-11-07 |
2023-09-06 |
Merck Sharp & Dohme LLC |
CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
|
|
US11046769B2
(en)
|
2018-11-13 |
2021-06-29 |
Compass Therapeutics Llc |
Multispecific binding constructs against checkpoint molecules and uses thereof
|
|
US20220362333A1
(en)
*
|
2019-07-26 |
2022-11-17 |
Board Of Trustees Of Michigan State University |
Methods Of Preventing Or Treating Fatty Degeneration Of Skeletal Muscle
|
|
EP4041392A1
(en)
|
2019-10-08 |
2022-08-17 |
Nectin Therapeutics Ltd. |
Antibodies against the poliovirus receptor (pvr) and uses thereof
|
|
IL292758A
(en)
*
|
2019-11-05 |
2022-07-01 |
Merck Patent Gmbh |
Combined inhibition of pd-1, tgfb and tigit for the treatment of cancer
|
|
US20230057899A1
(en)
|
2019-12-05 |
2023-02-23 |
Compugen Ltd. |
Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing
|
|
US20230037966A1
(en)
*
|
2020-01-07 |
2023-02-09 |
The Trustees Of The University Of Pennsylvania |
Source specific exosomes for determining avoidance of cancer treatment and avoidance of checkpoint inhibitor therapies
|
|
WO2021216468A1
(en)
*
|
2020-04-19 |
2021-10-28 |
Askgene Pharma Inc. |
Human tigit specific single domain antibodies and methods of use
|
|
JP7512394B2
(ja)
|
2020-05-06 |
2024-07-08 |
ドラゴンフライ セラピューティクス， インコーポレイテッド |
Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質
|
|
KR20230024368A
(ko)
|
2020-06-18 |
2023-02-20 |
제넨테크, 인크. |
항-tigit 항체 및 pd-1 축 결합 길항제를 사용한 치료
|
|
CN111763660A
(zh)
*
|
2020-08-07 |
2020-10-13 |
南京大学 |
一种重组溶瘤痘苗病毒及其制备方法和应用
|
|
JP2024503508A
(ja)
|
2021-01-15 |
2024-01-25 |
シージェン インコーポレイテッド |
免疫調節性抗体－薬物コンジュゲート
|
|
BR112023015561A2
(pt)
|
2021-02-03 |
2023-11-14 |
Univ Minnesota |
Compostos imunoestimuiladores e conjugados
|
|
EP4301774A4
(en)
|
2021-03-03 |
2025-08-13 |
Dragonfly Therapeutics Inc |
METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
|
|
CN113030487B
(zh)
*
|
2021-03-31 |
2023-11-10 |
山东大学齐鲁医院 |
Cd155在宫颈癌诊治中的应用
|
|
AR125753A1
(es)
|
2021-05-04 |
2023-08-09 |
Agenus Inc |
Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
|
|
WO2023010094A2
(en)
|
2021-07-28 |
2023-02-02 |
Genentech, Inc. |
Methods and compositions for treating cancer
|
|
WO2023020625A1
(zh)
*
|
2021-08-20 |
2023-02-23 |
中山康方生物医药有限公司 |
包含抗TIGIT抗体和TGF-βR的融合蛋白、其药物组合物及用途
|
|
WO2023056403A1
(en)
|
2021-09-30 |
2023-04-06 |
Genentech, Inc. |
Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
|
|
KR102680316B1
(ko)
*
|
2021-11-01 |
2024-07-01 |
오토텔릭바이오 주식회사 |
안티센스 올리고뉴클레오타이드
|
|
WO2023178192A1
(en)
|
2022-03-15 |
2023-09-21 |
Compugen Ltd. |
Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
|
|
CN115043910B
(zh)
*
|
2022-03-25 |
2023-04-07 |
湖南中晟全肽生化有限公司 |
抑制tigit与cd155结合的多肽及其应用
|
|
EP4518905A1
(en)
|
2022-05-06 |
2025-03-12 |
Seagen Inc. |
Immunomodulatory antibody-drug conjugates
|
|
KR20250022049A
(ko)
|
2022-06-07 |
2025-02-14 |
제넨테크, 인크. |
항-pd-l1 길항제 및 항-tigit 길항제 항체를 포함하는, 폐암 치료의 효율을 결정하는 방법
|
|
JP2025525904A
(ja)
|
2022-08-03 |
2025-08-07 |
シージェン インコーポレイテッド |
免疫刺激性抗ｐｄ－ｌ１－薬物コンジュゲート
|
|
EP4321522A1
(en)
|
2022-08-12 |
2024-02-14 |
Seagen Inc. |
Cytotoxic compounds and conjugates thereof
|
|
CN116284395B
(zh)
*
|
2022-12-12 |
2024-11-08 |
合肥天港免疫药物有限公司 |
抗cd155的抗体及其应用
|
|
TW202515608A
(zh)
|
2023-06-26 |
2025-04-16 |
以色列商坎布根有限公司 |
Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
|